CAR-T细胞构建技术研究进展  

Advances in chimeric antigen receptor T cell immunotherapy construction technology

作　　者：张苹 翟建昭 刘在栓 赵旭东(综述) 武永康(审校)[1] ZHANG Ping;ZHAI Jianzhao;LIU Zaishuan;ZHAO Xudong;WU Yongkang(Department of Laboratory Medicine,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China;Department of Tumor Animal Model Creation and Application,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China)

机构地区：[1]四川大学华西医院实验医学科,四川成都610041 [2]四川大学华西医院肿瘤动物模型创制及应用研究室,四川成都610041

出　　处：《国际检验医学杂志》2021年第9期1125-1129,共5页International Journal of Laboratory Medicine

基　　金：四川省科技厅项目(2020YFS0125);四川省成都市科技局项目(2019-GH02-00006-HZ、2019-YF05-00463-SN);四川大学华西医院学科卓越发展1·3·5工程临床研究孵化项目(2020HXFH038)。

摘　　要：嵌合抗原受体T细胞免疫疗法(CAR-T)被认为是最有潜力的癌症治疗方法,并取得了良好的临床疗效。随着CAR-T大规模应用,该技术的局限性也逐渐暴露出来,如治疗效果差、疾病复发、不良反应多等。这使得制造结构更优、安全性更高、效能更佳的CAR-T细胞成为临床所需。了解CAR-T的制造过程,掌握技术进展,是构建理想的CAR-T细胞的关键。本文以CAR-T细胞构建技术为中心,着重综述嵌合抗原受体各组分的构建及基因转导技术的研究进展,并就符合药品生产质量管理规范(GMP)标准的CAR-T细胞产品进行描述,最后对该技术发展及推广应用进行展望。Chimeric antigen receptor T cell immunotherapy(CAR-T)is considered to be the most promising treatment method and has achieved good clinical efficacy.With the large-scale clinical application of CAR-T,the limitations of this technology are gradually exposed,such as poor therapeutic effect,disease recurrence and a large number of adverse reactions.This makes the manufacture of CAR-T cells with better structure,higher safety and better efficiency clinically necessary.Understanding the manufacturing process of CAR-T and mastering the technological advances is the key to construct ideal CAR-T cells.This review focuses on CAR-T cell construction technology,especially in the development of chimeric antigen receptor component construction and gene transduction technology,and describes CAR-T cell products in line with the Good Manufactured Practices(GMP).Finally,the development,promotion and application of this technology are prospected.

关 键 词：嵌合抗原受体T细胞免疫疗法 嵌合抗原受体 构建 基因转导 

分 类 号：R392[医药卫生—免疫学]